Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

BACR & ECMC: Therapeutic interventions for cancer prevention /
Update on CaPP3 in high risk populations

18th - 19th Jul 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.08.16
Views: 1480

Prof Sir John Burn – Institute of Genetic Medicine, Newcastle, UK

Prof Sir Burn speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about the mechanism by which aspirin can prevent colorectal cancer.

He describes the CaPP studies for the intervention and prevention of colorectal cancers, using patients with an identified genetic predisposition towards certain types of cancer as a pre-diagnosed population, and how this can benefit wider health care.

With the example of aspirin, Prof Sir Burn describes ongoing studies of different dosage to determine its minimum level for cancer prevention, especially for high-risk subgroups.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation